North American Solitaire Stent Retriever Acute Stroke registry: Post-marketing revascularization and clinical outcome results

Osama O. Zaidat, Alicia C. Castonguay, Rishi Gupta, Chung Huan J. Sun, Coleman Martin, William E. Holloway, Nils Mueller-Kronast, Joey D. English, Italo Linfante, Guilherme Dabus, Tim W. Malisch, Franklin A. Marden, Hormozd Bozorgchami, Andrew Xavier, Ansaar T. Rai, Michael T. Froehler, Aamir Badruddin, Thanh N. Nguyen, M. Asif Taqi, Michael G. AbrahamVallabh Janardhan, Hashem Shaltoni, Roberta Novakovic, Albert J. Yoo, Alex Abou-Chebl, Peng R. Chen, Gavin W. Britz, Ritesh Kaushal, Ashish Nanda, Mohammad A. Issa, Raul G. Nogueira

Research output: Contribution to journalArticle

76 Scopus citations

Abstract

Background Limited post-marketing data exist on the use of the Solitaire FR device in clinical practice. The North American Solitaire Stent Retriever Acute Stroke (NASA) registry aimed to assess the real world performance of the Solitaire FR device in contrast with the results from the SWIFT (Solitaire with the Intention for Thrombectomy) and TREVO 2 (Trevo versus Merci retrievers for thrombectomy revascularization of large vessel occlusions in acute ischemic stroke) trials. Methods The investigator initiated NASA registry recruited North American sites to submit retrospective angiographic and clinical outcome data on consecutive acute ischemic stroke (AIS) patients treated with the Solitaire FR between March 2012 and February 2013. The primary outcome was a Thrombolysis in Myocardial Ischemia (TIMI) score of ≥2 or a Treatment in Cerebral Infarction (TICI) score of ≥2a. Secondary outcomes were 90 day modified Rankin Scale (mRS) score, mortality, and symptomatic intracranial hemorrhage. Results 354 patients underwent treatment for AIS using the Solitaire FR device in 24 centers. Mean time from onset to groin puncture was 363.4±239 min, mean fluoroscopy time was 32.9±25.7 min, and mean procedure time was 100.9±57.8 min. Recanalization outcome: TIMI ≥2 rate of 83.3% (315/354) and TICI ≥2a rate of 87.5% (310/354) compared with the operator reported TIMI ≥2 rate of 83% in SWIFT and TICI ≥2a rate of 85% in TREVO 2. Clinical outcome: 42% (132/315) of NASA patients demonstrated a 90 day mRS ≤2 compared with 37% (SWIFT) and 40% (TREVO 2). 90 day mortality was 30≥2% (95/315) versus 17≥2% (SWIFT) and 29% (TREVO 2). Conclusions The NASA registry demonstrated that the Solitaire FR device performance in clinical practice is comparable with the SWIFT and TREVO 2 trial results.

Original languageEnglish (US)
Pages (from-to)584-588
Number of pages5
JournalJournal of NeuroInterventional Surgery
Volume6
Issue number8
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Zaidat, O. O., Castonguay, A. C., Gupta, R., Sun, C. H. J., Martin, C., Holloway, W. E., Mueller-Kronast, N., English, J. D., Linfante, I., Dabus, G., Malisch, T. W., Marden, F. A., Bozorgchami, H., Xavier, A., Rai, A. T., Froehler, M. T., Badruddin, A., Nguyen, T. N., Taqi, M. A., ... Nogueira, R. G. (2014). North American Solitaire Stent Retriever Acute Stroke registry: Post-marketing revascularization and clinical outcome results. Journal of NeuroInterventional Surgery, 6(8), 584-588. https://doi.org/10.1136/neurintsurg-2013-010895